Goodwin Advises Frazier Healthcare Partners on Majority Investment in ATUM
The Private Equity team advised Frazier Healthcare Partners on the completion of its majority investment in ATUM, a bioengineering company specializing in gene design, protein optimization, and cell line development. The transaction was completed in partnership with co-investors, including Frazier Life Sciences, and ATUM’s existing founders and management team.
Founded in 1991, Frazier Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. Since its inception, Frazier has raised over $11 billion of capital for private funds and co-investment opportunities and has invested in more than 200 companies over the past 35 years. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier is headquartered in Seattle, Washington, with an office in New York City, and invests broadly across the US, Canada, and Europe.
The Goodwin team was led by Jared Spitalnick, Colin Carley, and William Tevlin. Debt finance advice was provided by Jennifer Bralower and Emily Josef.
For more information on the deal, please read the press release.